OpGen Raises $17M to Market Optical Mapping System

Sep 28, 2010

Premium

This story was originally published Sept. 27

OpGen, a commercial provider of optical restriction-mapping technology, has raised $17 million in Series B financing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Keep Them or Not?

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

Dunno Whose It Is

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

Knowing Risk From a Young Age

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

Science Translational Medicine Paper Finds Drug Combo Boosts KRAS Inhibitor Efficacy in Lung Cancer

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.

Featured White Papers

The 'Dark Matter' of Cancer Genomics: Revealing Undetected Structural Variants

Analytical Validation of the Oncomine Pan-Cancer Cell-Free Assay

A High-Performance Solution Combining CleanPlex OncoZoom Cancer Hotspot Panel and SOPHiA AI for Rapid Characterization of Somatic Mutations

BlueBee Data Security & Compliance

Oct

23

Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.

Menu